Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Sudden death; Refusal to eat; Deterioration in general condition; Restlessness; cough; COVID-19 PCR test/COVID-19 rapid POC test : positiv/positive NA; This is a spontaneous report from a non-contactable physician downloaded from the Medicines Agency (MA) Regulatory Authority-WEB DE-PEI-PEI2021002569. An 83-years-old male patient received first dose of bnt162b2 (COMIRNATY, Lot# no.: EM0477), via an unspecified route of administration on 01Jan2021 at single dose for covid-19 immunisation. Medical history included Dementia Alzheimer''s type, Coxarthrosis, Basal cell carcinoma, Squamous cell carcinoma, Prostatic adenoma. The patient''s concomitant medications were not reported. The patient experienced refusal to eat on 15Jan2021, cough on 12Jan2021, deterioration in general condition on 15Jan2021, restlessness on 12Jan2021. Clinical course reported as: 11 day(s) after vaccination the patient developed Cough and Restlessness and General physical health deterioration and Diet refusal, lasting for 12 day(s). The patient underwent lab tests and procedures which included COVID-19 PCR test: positiv/positive NA on 11Jan2021, COVID-19 rapid POC test: positiv/positive NA on 10Jan2021. The patient died on 23Jan2021. It was not reported if an autopsy was performed. Events refusal to eat, cough, deterioration in general condition, restlessness were reported as serious with seriousness criterion death. Cause of death was reported as sudden death. No follow-up attempts are possible, batch number already obtained.; Reported Cause(s) of Death: Restlessness; General physical health deterioration; cough; Refusal to eat; Sudden death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166